Drug Trial Radar · NCT05938465
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 6, 2023
Primary completion
May 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Exegi Pharma, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- The Emmes Company, LLC
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Conditions
- Ileal Pouch
Interventions
EXE-346Biological
EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
PlaceboOther
Placebo contains excipients maltose and silicon dioxide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 4 weeks
- Phase 1b: Number of Participants with Abnormal Physical ExaminationsTime frame: 4 weeks
- Phase 1b: Number of Participants with Abnormal Vital SignsTime frame: 4 weeks
- Phase 1b: Number of Participants with Abnormal Safety LabsTime frame: 4 weeks
- Phase 1b: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 4 weeks
- Phase 2: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 8 weeks
- Phase 2: Number of Participants with Abnormal Physical ExaminationsTime frame: 8 weeks
- Phase 2: Number of Participants with Abnormal Vital SignsTime frame: 8 weeks
- Phase 2: Number of Participants with Abnormal Safety LabsTime frame: 8 weeks
- Phase 2: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 8 weeks
- Phase 2: Change in Total Daily Bowel Movement FrequencyTime frame: 8 weeks
- Phase 2 Open Label: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)Time frame: 8 weeks
- Phase 2 Open Label: Number of Participants with Abnormal Physical ExaminationsTime frame: 8 weeks
- Phase 2 Open Label: Number of Participants with Abnormal Vital SignsTime frame: 8 weeks
- Phase 2 Open Label: Number of Participants with Abnormal Safety LabsTime frame: 8 weeks
- Phase 2 Open Label: Study Treatment Discontinuation Due to Treatment Emergent Adverse Events (TEAEs)Time frame: 8 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Mayo Clinic - Florida (Inflammatory Bowel Disease Center)
Jacksonville, Florida · Recruiting
Corewell Health
Grand Rapids, Michigan · Recruiting
Mayo Clinic Department of Gastroenterology
Rochester, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Penn State Health (Milton S. Hershey Medical Center)
Hershey, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.